Daily Archives: April 11, 2020
Proton therapy is the best option for lung cancer patients
April 11th, 2020 Lung cancer, Proton therapyLung cancer and proton therapyThe lungs are adjacent to some of the most sensitive and important organs and tissues, including the heart, esophagus, and spinal cord. Only about 20% of lung tumors can be treated by surgery; other patients genera.... Read More
Radiofrequency ablation treatment for lung cancer patients
April 11th, 2020 Lung cancerLung cancer is one of the most common causes of human death due to tumors, and its morbidity and mortality rate have ranked first in cities. The pathology is mainly non-small cell lung cancer (NSCLC), accounting for about 85%. Most patients ar.... Read More
Afatinib is more effective than gefitinib in treating non-small cell lung cancer
April 11th, 2020 Lung cancerThe results of the LUX-Lung 7 study show that a head-to-head Phase IIb clinical study compared afatinib and gefitinib in the treatment of tumors with EGFR mutations The results are published in the "Lancet Oncology" magazine.Chief researcher and.... Read More
NCCN Guidelines for Small Cell Lung Cancer V2.2016
April 11th, 2020 Lung cancerThe second edition of the 2016 NCCN Guidelines for Small Cell Lung Cancer (V2.2016) mainly updates the following parts based on V2.2015:Lung cancer preliminary assessment stage updateSCL-2: Some patients can be selected for bone marrow aspiratio.... Read More
Nivolumab plus Ipilimumab as first-line treatment for stage IV non-small cell lung cancer
April 11th, 2020 Lung cancerRegistration: ClinicalTrials.govLast updated: January 25, 2016Main ID: NCT02659059Registration Date: January 15, 2016Main sponsor: Bristol-Myers SquibbOpen topic: Nivolumab plus Ipilimumab as a first-line treatment for stage IV non-small cell lu.... Read More
Third-generation EGFR targeted drug Tagrisso for lung cancer treatment
April 11th, 2020 Lung cancerThe US FDA today approved the official launch of AstraZeneca's new drug AZD9291! The trade name and common name of AZD9291 are called Tagrisso or Osimertinib. This is the third generation of TKI targeted drugs for the treatment of advanced non.... Read More
Precision medicine for lung cancer
April 11th, 2020 Lung cancerLung cancer problemPerhaps it is because of the direct feeling of the respiratory system. As the haze continues, we feel more and more people suffering from lung cancer around us. Indeed, lung cancer is the fastest growing malignant tumor in th.... Read More
EGFR monoclonal antibody Portrazza for advanced lung squamous cell carcinoma
April 11th, 2020 Lung cancerThe US Food and Drug Administration (hereinafter referred to as FDA) approved Portrazza (necitumumab) in combination with gemcitabine and cisplatin in the treatment of advanced (metastatic) squamous non-small cell lung cancer on November 24, 201.... Read More
The safety and efficacy of MPDL3280A combined with platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer
April 11th, 2020 Lung cancerMPDL3280A, which retains the PD-L2 / PD-1 interaction, potentially reduces autoimmune lung toxicity, and has a good effect on advanced NSCLC. Platinum-based chemotherapy is still the standard first-line treatment for non-small cell lung cancer,.... Read More
Treatment of central lung cancer with speed knife
April 11th, 2020 Lung cancerTreatment of non-small cell lung cancerThe treatment of lung cancer mainly uses surgery, radiotherapy and chemotherapy, and surgery is still the most effective method for the treatment of lung cancer in the early and middle stages. However, for.... Read More